IL-17 regulates gene expression and protein synthesis of the complement system, C3 and factor B, in skin fibroblasts

Clinical and Experimental Immunology

Volumn 120, Issue 1, 2000, Pages 22-29

  Katz, Yitzhak ^a,b   Nadiv, O ^b   Rapoport, M J ^b   Loos, M ^c  

^a TEL AVIV UNIVERSITY   (Israel)

^b ASSAF HAROFEH MEDICAL CENTER   (Israel)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Complement; Fibroblasts; IL 17; Tumour necrosis factor

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 17; TUMOR NECROSIS FACTOR;

ARTICLE; COMPLEMENT ACTIVATION; CYTOKINE RELEASE; DRUG EFFECT; EPITHELIUM CELL; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; KERATINOCYTE; MEMORY CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SKIN FIBROBLAST; SYNOVIOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 0034069815     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2000.01199.x     Document Type: Article

References (38)

1. Yao Z, Painter SL, Fanslow WC, Ulrich D, Macduff BM, Spriggs MK, Armitage RJ. Human IL-17: a novel cytokine derived from T cells. J Immunol 1995; 155:5483-6.
2. Fossiez F, Djossou O, Chomarat P et al. T cell IL-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996; 183:2593-603.
3. Teunissen MBM, Koomen CW, de Waal Malefyt R, Wierenga EA, Bos JB. Interleukin-17 and interferon-γ synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 1998; 111:645-9.
4. Attur MG, Patel RN, Abramson SB, Amin AR. IL-17 up-regulation of nitric oxide production in human osteoarthritis cartilage. Arthritis Rheum 1997; 40:1050-3.
5. Shalom-Barak T, Quach J, Lotz M. IL-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-κB. J Biol Chem 1998; 273:27467-73.
6. Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M, Mineau F, Pelletier JP. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-1β and TNF-α, by human macrophages. J Immunol 1998; 160:3513-21.
7. Chabaud M, Fossiez F, Taupin J-L, Miossec P. Enhancing effect of IL-17 on IL-1 induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol 1998; 161:409-14.
8. Aarvak T, Chabaud M, Miossec P, Natvig JB. IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol 1999; 162:1246-51.
9. Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L, Miossec P. Human IL-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999; 42:963-70.
10. Westacott CI, Sharif M. Cytokines in osteoarthritis: mediators or markers of joint destruction? Semin Arthritis Rheum 1996; 25:254-72.
11. Katz Y, Strunk RC. IL-1 and TNF: similarities and differences in stimulation of expression of alternative pathway of complement and IFN-b2/IL-6 genes in human fibroblasts. J Immunol 1989; 142:3862-7.
12. Katz Y, Strunk RC. Enhanced synthesis of factor B by tumor necrosis factor in human skin fibroblasts is decreased by IL-4. J Immunol 1990; 144:4675-80.
13. Katz Y, Stav D, Barr J, Passwell JH. IL-13 results in differential regulation of the complement proteins C3 and factor B in tumor necrosis factor (TNF)-stimulated fibroblasts. Clin Exp Immunol 1995; 101:150-6.
14. Dechanet J, Taupin JL, Chomarat P, Rissoan MC, Moreau JF, Banchereau J, Miossec P. Interleukin-4 but not interleukin-10 inhibits the production of leukemia inhibitory factor by rheumatoid synovium and synoviocytes. Eur J Immunol 1994; 24:3222-8.
15. Sugiyama E, Kuroda A, Taki H, Ikemoto M, Hori T, Yamashita N, Maruyama M, Kobayashi M. IL-10 cooperates with IL-4 to suppress inflammatory cytokine production by freshly prepared adherent rheumatoid synovial cells. J Rheumatol 1995; 22:2020-6.
16. Isomaki P, Luukkainen R, Toivanen P, Punnonen J. The presence of interleukin-13 in rheumatoid synovium and its antiinflammatory effects on synovial fluid macrophages from patients with rheumatoid arthritis. Arthritis Rheum 1996; 39:1693-702.
17. Bessis N, Boissier MC, Ferrara P, Blankenstein T, Fradelizi D, Fournier C. Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13. Eur J Immunol 1996; 26:2399-403.
18. Miossec P, Van den Berg W. Th1/Th2 cytokine balance in arthritis. Arthritis Rheum 1997; 40:2105-15.
19. Bessis N, Chiocchia G, Kollias G, Minty A, Fournier C, Fradelizi D, Boissier MC. Modulation of proinflammatory cytokine production in tumor necrosis factor-alpha (TNF-alpha)-transgenic mice by treatment with cells engineered to secrete interleukin-4, interleukin-10 or interleukin-13. Clin Exp Immunol 1998; 111:391-6.
20. Katz Y, Strunk RC. Synovial fibroblast-like cells synthesize seven proteins of the complement system. Arthritis Rheum 1988; 31:1365-70.
21. DeBruijn MHL, Fey GH. Human complement component C3, cDNA coding sequence and derived primary structure. Proc Natl Acad Sci USA 1985; 82:708-12.
22. Woods DE, Markham AF, Ricker AT, Goldberger G, Colten HR. Isolation of cDNA clones for the human complement protein factor B, a class III major histocompatibility complex gene product. Proc Natl Acad Sci USA 1982; 79:5661-5.
23. Fishelzon Z. Complement C3: a molecular mosaic of binding sites. Mol Immunol 1991; 28:545-52.
24. Erdei A, Fust G, Gergely J. The role of C3 in the immune response. Immunol Today 1991; 12:332-7.
25. Fearon DT, Austen KF. Current concepts in immunology: the alternative pathway of the complement - a system for host resistance to microbial infection. N Engl J Med 1980; 303:259-63.
26. Katz Y, Cole FS, Strunk RC. Synergism between gamma interferon and lipopolysaccharide for synthesis of factor B, but not C2, in human fibroblasts. J Exp Med 1988; 167:1-14.
27. Feltkamp TEW, Aarden LA, Lucas CJ, Verweij CL, De Vries RRP. Genetic risk factors for autoimmune diseases. Immunol Today 1999; 20:10-12.
28. Alexopoulou L, Pasparakis M, Kollias G. A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling. Eur J Immunol 1997; 27:2588-92.
29. Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of Etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340:253-9.
30. Kavanaugh AF. Anti-tumor necrosis factor alpha monoclonal antibody therapy for rheumatoid arthritis. Rheum Dis Clin North Am 1998; 24:593-614.
31. Camussi G, Lupia E. The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis. Drugs 1998; 55:613-20.
32. Nakazato Y, Hayashida T, Kanno Y, Okada H, Suzuki H, Saruta T. Interleukin (IL-1)-1 and IL-4 synergistically stimulate NF-IL-6 activity and IL-6 production in human mesangial cells. Kidney Int 1998; 54:71-79.
33. Suzuki H, Sugiyama E, Tunru IS, Yamashita N, Hamazaki T, Kobayashi M. Suppressive effect of interleukin-4 (IL-4) on IL-6 production by adherent rheumatoid synovial cells. Clin Immunol Immunopathol 1993; 66:67-72.
34. Gabay C, Kushner I. Acute phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340:448-54.
35. Muller-Eberhard HJ. Molecular organization and function of the complement system. Annu Rev Biochem 1988; 57:321-47.
36. Carroll MC. The lupus paradox. Nature Genet 1998; 19:3-4.
37. Van den Bosch F, Russell A, Chair MB et al. rHIL-4 in subjects with active rheumatoid arthritis: a phase I dose escalating safety study. Arthritis Rheum 1998; 41 (Suppl.):S56.
38. Maini RN, Paulus H, Breedveld FC et al. rHIL-10 in subjects with active rheumatoid arthritis: a phase I and cytokine response study. Arthritis Rheum 1997; 40 (Suppl.):S224.